These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 7577481)

  • 1. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Br J Cancer; 1995 Nov; 72(5):1270-7. PubMed ID: 7577481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economics of lung cancer management in Canada.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Lung Cancer; 1996 Feb; 14(1):19-29. PubMed ID: 8696718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of combined modality interventions for stage III non-small-cell lung cancer.
    Evans WK; Will BP; Berthelot JM; Earle CC
    J Clin Oncol; 1997 Sep; 15(9):3038-48. PubMed ID: 9294466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs.
    Will BP; Le Petit C; Berthelot JM; Tomiak EM; Verma S; Evans WK
    Br J Cancer; 1999 Mar; 79(9-10):1428-36. PubMed ID: 10188886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment pathways, resource use and costs in the management of small cell lung cancer.
    Oliver E; Killen J; Kiebert G; Hutton J; Hall R; Higgins B; Bourke S; Paschen B
    Thorax; 2001 Oct; 56(10):785-90. PubMed ID: 11562518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost analysis of lung cancer management in South Western Sydney.
    Kang S; Koh ES; Vinod SK; Jalaludin B
    J Med Imaging Radiat Oncol; 2012 Apr; 56(2):235-41. PubMed ID: 22498199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists.
    Dudani S; Leighl NB; Ho C; Pantarotto JR; Zhu X; Zhang T; Wheatley-Price P
    Lung Cancer; 2016 Apr; 94():74-80. PubMed ID: 26973210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module.
    Evans WK
    Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-56-S7-63. PubMed ID: 9194482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimates of the lifetime costs of breast cancer treatment in Canada.
    Will BP; Berthelot JM; Le Petit C; Tomiak EM; Verma S; Evans WK
    Eur J Cancer; 2000 Apr; 36(6):724-35. PubMed ID: 10762744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economics of the clinical management of lung cancer in France: an analysis using a Markov model.
    Chouaïd C; Molinier L; Combescure C; Daurès JP; Housset B; Vergnenègre A
    Br J Cancer; 2004 Jan; 90(2):397-402. PubMed ID: 14735183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada.
    Louie AV; Rodrigues GB; Palma DA; Senan S
    Oncologist; 2014 Aug; 19(8):880-5. PubMed ID: 24951606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lifetime costs of colon and rectal cancer management in Canada.
    Maroun J; Ng E; Berthelot JM; Le Petit C; Dahrouge S; Flanagan WM; Walker H; Evans WK
    Chronic Dis Can; 2003; 24(4):91-101. PubMed ID: 14733758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct treatment costs for patients with lung cancer from first recurrence to death in france.
    Braud AC; Lévy-Piedbois C; Piedbois P; Piedbois Y; Livartovski A; Le Vu B; Trédaniel J; Reboul F; Brewer Y; Talbi S; Blanchon F; Paschen B; Durand-Zaleski I
    Pharmacoeconomics; 2003; 21(9):671-9. PubMed ID: 12807368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
    Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
    Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population-based study of the resource utilization and costs of managing resectable non-small cell lung cancer.
    Mahar AL; Coburn NG; Johnson AP
    Lung Cancer; 2014 Nov; 86(2):281-7. PubMed ID: 25267166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic non-small cell lung cancer: costs associated with disease progression.
    Fox KM; Brooks JM; Kim J
    Am J Manag Care; 2008 Sep; 14(9):565-71. PubMed ID: 18778171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
    Vinod SK; Wai E; Alexander C; Tyldesley S; Murray N
    J Thorac Oncol; 2012 Jul; 7(7):1155-63. PubMed ID: 22617240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Adjuvant Atezolizumab on Recurrences Avoided and Treatment Cost Savings for Patients with Stage II-IIIA Non-Small Cell Lung Cancer in Canada.
    Chu Q; Sripada K; Vaselenak S; Jovanoski N; Arnold M
    Curr Oncol; 2024 Jun; 31(6):3301-3310. PubMed ID: 38920734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain).
    Corral J; Espinàs JA; Cots F; Pareja L; Solà J; Font R; Borràs JM
    BMC Health Serv Res; 2015 Feb; 15():70. PubMed ID: 25889153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.